Robert S. Wallis spends much of his time researching Immunology, Tuberculosis, Mycobacterium tuberculosis, Tumor necrosis factor alpha and Infliximab. Robert S. Wallis frequently studies issues relating to Tuberculin and Immunology. His Tuberculosis research includes themes of Virology, Acquired immunodeficiency syndrome, Intensive care medicine, Immunopathology and Risk factor.
Robert S. Wallis interconnects Culture conversion, Cellular immunity, Lung injury and Microbiology in the investigation of issues within Mycobacterium tuberculosis. His Tumor necrosis factor alpha research incorporates themes from Immune system, Antibody and Cytokine. His work deals with themes such as Paradoxical reaction, Etanercept and Monoclonal antibody, which intersect with Infliximab.
His primary scientific interests are in Tuberculosis, Immunology, Mycobacterium tuberculosis, Tumor necrosis factor alpha and Internal medicine. His studies deal with areas such as Clinical trial, Virology and Intensive care medicine as well as Tuberculosis. As a part of the same scientific study, Robert S. Wallis usually deals with the Immunology, concentrating on Tuberculin and frequently concerns with Antimycobacterial.
His work investigates the relationship between Mycobacterium tuberculosis and topics such as Microbiology that intersect with problems in Mycobacterium bovis. His study in Tumor necrosis factor alpha is interdisciplinary in nature, drawing from both Necrosis, Blockade, Rheumatoid arthritis and Monoclonal antibody. In his research, Pyrazinamide is intimately related to Surgery, which falls under the overarching field of Internal medicine.
His main research concerns Tuberculosis, Immunology, Internal medicine, Mycobacterium tuberculosis and Sputum culture. His Tuberculosis study combines topics from a wide range of disciplines, such as Clinical trial, Intensive care medicine, Pulmonary function testing, Lung injury and Pharmacology. Robert S. Wallis combines Immunology and In patient in his research.
Robert S. Wallis has included themes like Gastroenterology and Drug in his Internal medicine study. The study incorporates disciplines such as Whole blood, Ex vivo, Antibiotics, Immune system and Blood proteins in addition to Mycobacterium tuberculosis. His research in Sputum culture focuses on subjects like Biomarker, which are connected to Drug development and Microbiology.
Robert S. Wallis focuses on Tuberculosis, Mycobacterium tuberculosis, Immunology, Clinical trial and Internal medicine. His research in Tuberculosis intersects with topics in Infectious disease, Immune system, Intensive care medicine, Varicella zoster virus and Drug resistance. His Drug resistance study integrates concerns from other disciplines, such as Antimicrobial, Malaria and Pharmacology.
His biological study deals with issues like Lung injury, which deal with fields such as Antimicrobial peptide production, Immunotherapy, Macrophage, Effector and Inflammation. In most of his Immunology studies, his work intersects topics such as Adverse effect. The Internal medicine study which covers Sputum that intersects with Alanine transaminase, Blood plasma, Blood Bactericidal Activity and Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
R. S. Wallis;M. S. Broder;J. Y. Wong;M. E. Hanson.
Clinical Infectious Diseases (2004)
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice
Robert S Wallis;Madhukar Pai;Madhukar Pai;Dick Menzies;Dick Menzies;T Mark Doherty.
The Lancet (2010)
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
I. Solovic;M. Sester;J. J. Gomez-Reino;H. L. Rieder.
European Respiratory Journal (2010)
Depressed T-Cell Interferon-γ Responses in Pulmonary Tuberculosis: Analysis of Underlying Mechanisms and Modulation with Therapy
Christina S. Hirsch;Zahra Toossi;Catherine Othieno;John L Johnson.
The Journal of Infectious Diseases (1999)
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks.
Robert S Wallis;Robert S Wallis.
Lancet Infectious Diseases (2008)
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J Boeree;Norbert Heinrich;Rob Aarnoutse;Andreas H Diacon.
Lancet Infectious Diseases (2017)
Biomarkers for tuberculosis disease activity, cure, and relapse
Robert S. Wallis;T. Mark Doherty;Phillip Onyebujoh;Mahnaz Vahedi.
Lancet Infectious Diseases (2009)
Advancing host-directed therapy for tuberculosis
Robert S. Wallis;Richard Hafner.
Nature Reviews Immunology (2015)
Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction
Robert S. Wallis;Michael Broder;John Wong;David Beenhouwer.
Clinical Infectious Diseases (2004)
Tuberculosis biomarkers discovery: developments, needs, and challenges
Robert S Wallis;Robert S Wallis;Robert S Wallis;Peter Kim;Stewart Cole;Debra Hanna.
Lancet Infectious Diseases (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: